Inflectra® (Infliximab)

Introducing Inflectra®/CT-P13* (infliximab)

Inflectra®/CT-P13* (infliximab) is the first approved‡§ biosimilar infliximab1.

Demonstrated comparable efficacy and safety profile to Remicade® in rigorous clinical studies for RA and AS1-3.

Via extrapolation, Inflectra® is licensed for all of the same clinical indications as Remicade®§,1-3.

Watch how infliximab blocks the functional activity of TNF-α

CT-P13* has more than 370,000 patients years of exposure across indications4.

Infliximab revolutionised the management of CD and UC5,6 for Gastroenterologists.
Infliximab is a cornerstone treatment for many inflammatory diseases – with more than 15 years of clinical experience across all indications5-12.

*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.

INFLECTRA® has demonstrated comparable efficacy and safety to Remicade® in rigorous clinical studies for RA and AS and, via extrapolation, is licensed for all the same clinical indications as Remicade®1-,3.

§EMA guidelines state that “Extrapolation of clinical efficacy and safety data to other indications of the reference mAb, not specifically studied during the clinical development of the biosimilar mAb, is possible based on the results of the overall evidence provided from the comparability exercise and with adequate justification”1,3.

Remicade® is a registered trademark of MSD.

EMA, European Medicines Agency; mAb, Monoclonal antibody RA, Rheumatoid arthritis; AS, Ankylosing spondylitis; CD, Crohn's disease; NICE, The National Institute for Health and Care Excellence; BSR, British Society for Rheumatology; BSG, British Society of Gastroenterology; ECCO, European Crohn's and Colitis Organisation; TDM, Therapeutic drug monitoring.


PP-IFA-GBR-0448.  December 2020